Libtayo (cemiplimab) shows sustained survival benefit at five years in advanced non-small cell lung cancer

Posted on September 9, 2024 by Vaseline

Recent data from WCLC show that Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared with chemotherapy.

The WCLC presentation will also discuss data on overall survival, progression-free survival, and response rate among patients who added chemotherapy to Libtayo after disease progression

Display